ArticleStem cell research & therapy2026
Exosomal miR-181d-5p derived from distal airway stem cells inhibit apoptosis of pulmonary vascular endothelial cells in COPD mice by targeting PDAP1.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study was to investigate the role of exosomes derived from distal airway stem cells (DASC) in apoptosis of pulmonary vascular endothelial cells (PVEC) in chronic obstructive pulmonary disease (COPD) and to explore the potential mechanisms.
methodsCigarette smoke extract (CSE) plus cigarette smoke (CS)-induced COPD mice were treated with DASC and exosomes. The microRNA (miR) sequencing of exosomes was performed to explore the underlying mechanisms. We determined the expression of miR-181d-5p and PDAP1 in patients with COPD.
resultsCompared with control mice, DASC and exosomes derived from DASC could alleviate emphysema changes, decrease the mean linear intercept and alveolar destructive index, reduce apoptosis of PVEC in COPD mice. Furthermore, miR-181d-5p was significantly decreased in exosomes derived from COPD mice DASC when compared with exosomes derived from normal mice DASC. The knockdown of miR-181d-5p in exosomes derived from DASC could weaken its effects in alleviating emphysema and apoptosis of PVEC, increase the expression of PDAP1, and decrease the expression of miR-181d-5p. The overexpression of miR-181d-5p and knockdown of PDAP1 could significantly reduce apoptosis in CSE-induced PVEC. Furthermore, the overexpression of PDAP1 could reverse the anti-apoptotic effect of miR-181d-5p on CSE-induced PVEC. Finally, the expression of miR-181d-5p was decreased in patients with COPD and positively related to pulmonary function, while the expression of PDAP1 was increased and negatively related to pulmonary function.
conclusionsExosomes derived from DASC could alleviate lung injury in COPD. The mechanism may be to reduce the apoptosis of PVEC by delivering miR-181d-5p by targeting PDAP1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.